Inventor · disambiguated record
Anthony G. Doyle
Also filed as: DOYLE ANTHONY · DOYLE ANTHONY G · DOYLE ANTHONY GERARD
31 granted patents·17 pending applications·104 citations·filing 2006–2025
96Inventor score
Files withTEVA PHARMACEUTICALS AUSTRALIA PTY LTD19CEPHALON LLC10CEPHALON INC5CEPHALON AUSTRALIA PTY LTD4CLARKE ADAM WILLIAM2
Top patents by PatentIndex Score
48 records- 0195US10138296B2Antibodies that specifically bind to TL1ACEPHALON INC·Filed 2016·Granted Nov 27, 2018·17 cites·34 claims
- 0293US11220549B2Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseasesCEPHALON INC·Filed 2018·Granted Jan 11, 2022·8 cites·31 claims
- 0391US10232041B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Mar 19, 2019·9 cites·21 claims
- 0490US10822422B2Antibodies against TL1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Granted Nov 3, 2020·10 cites·13 claims
- 0590US9636334B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 2, 2017·9 cites·20 claims
- 0689US11725052B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2021·Granted Aug 15, 2023·2 cites·26 claims
- 0787US9963515B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 8, 2018·5 cites·27 claims
- 0887US9611322B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Granted Apr 4, 2017·6 cites·18 claims
- 0987US2025353919A1Antibodies Against TL1A and Uses ThereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2025·Application pending·0 cites
- 1086US10544199B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted Jan 28, 2020·7 cites·20 claims
- 1185US11267883B2Antibodies that specifically bind to human IL-15 and uses thereofCEPHALON INC·Filed 2017·Granted Mar 8, 2022·5 cites·27 claims
- 1285US8563697B2Anti-IL-12/IL-23 antibodiesCLARKE ADAM WILLIAM·Filed 2009·Granted Oct 22, 2013·11 cites·11 claims
- 1384US2025179202A1Antibodies That Specifically Bind to TL1A and Methods of Treating Skin DiseaseCEPHALON LLC·Filed 2024·Application pending·0 cites
- 1483US12410256B2Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseasesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 1583US11319356B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2019·Granted May 3, 2022·2 cites·18 claims
- 1683US10981986B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Apr 20, 2021·2 cites·21 claims
- 1782US11111292B2Anti-IL-5 antibodiesCEPHALON INC·Filed 2017·Granted Sep 7, 2021·3 cites·24 claims
- 1878US2024301076A1Anti-cxcr2 antibodies and uses thereofCEPHALON LLC·Filed 2024·Application pending·0 cites
- 1977US12384841B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2023·Granted Aug 12, 2025·0 cites·3 claims
- 2077US12162946B2Antibodies that specifically bind to TL1A and methods of treating gastrointestinal diseaseCEPHALON LLC·Filed 2021·Granted Dec 10, 2024·0 cites·31 claims
- 2175US11332534B2Anti-CXCR2 antibodies and uses thereofCEPHALON INC·Filed 2019·Granted May 17, 2022·1 cites·13 claims
- 2275US11117975B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2018·Granted Sep 14, 2021·1 cites·13 claims
- 2373US12018084B2Anti-CXCR2 antibodies and uses thereofCEPHALON LLC·Filed 2022·Granted Jun 25, 2024·0 cites·25 claims
- 2472US12281148B2Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereofCEPHALON LLC·Filed 2024·Granted Apr 22, 2025·0 cites·10 claims
- 2571US12410247B2Polynucleotides encoding antibodies that specifically bind to human IL-15CEPHALON LLC·Filed 2022·Granted Sep 9, 2025·0 cites·20 claims
- 2671US11253591B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2019·Granted Feb 22, 2022·0 cites·17 claims
- 2770US7846439B2Domain antibody constructCEPHALON AUSTRALIA PTY LTD·Filed 2007·Granted Dec 7, 2010·1 cites·4 claims
- 2869US9127057B2Anti-IL-23 heterodimer specific antibodiesCLARKE ADAM WILLIAM·Filed 2011·Granted Sep 8, 2015·2 cites·16 claims
- 2969US8470320B2Humanised antibodies with anti-tumour activityCLARKE ADAM W·Filed 2010·Granted Jun 25, 2013·2 cites·50 claims
- 3069US2022220184A1Interferon alpha 2b variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2022·Application pending·0 cites
- 3168US2021347904A1Antibodies against tl1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2020·Application pending·0 cites
- 3264US2014255302A1ANTIBODIES AGAINST TL1a AND USES THEREOFTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 3363US8263076B2Anti-inflammatory dAbWOOLVEN BENJAMIN P·Filed 2011·Granted Sep 11, 2012·1 cites·16 claims
- 3463US2024076343A1Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereofCEPHALON LLC·Filed 2023·Application pending·0 cites
- 3561US12358980B2Compositions and methods for anti-PACAP antibodiesCEPHALON LLC·Filed 2022·Granted Jul 15, 2025·0 cites·20 claims
- 3658US2008255343A1Chimeric antibodiesARANA THERAPEUTICS LTD·Filed 2008·Application pending·0 cites
- 3755US7981414B2Anti-inflammatory dAbCEPHALON AUSTRALIA PTY LTD·Filed 2006·Granted Jul 19, 2011·0 cites·10 claims
- 3854US8901279B2Humanized antibodies with anti-tumor activityTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2013·Granted Dec 2, 2014·0 cites·27 claims
- 3954US2008139790A1Chimeric antibodiesJENNINGS PHILIP A·Filed 2006·Application pending·0 cites
- 4054US2016367695A1Polypeptide constructs and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 4152US2014086922A1Anti-il-12/il-23 antibodiesCEPHALON AUSTRALIA PTY LTD·Filed 2013·Application pending·0 cites
- 4250US2013040383A1Nucleic acid molecules encoding anti-inflammatory domain antibodiesCEPHALON AUSTRALIA PTY LTD·Filed 2012·Application pending·0 cites
- 4350US2011319597A1Variant domain antibodiesSIMPSON RAINA JUI YU·Filed 2009·Application pending·0 cites
- 4447US2016264661A1Anti-il-12/il-23 antibodiesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 4545US2008095767A1Engineered antibodies with new world primate framework regionsPEPTECH LTD·Filed 2007·Application pending·0 cites
- 4642US2014286957A1ANTIBODIES TO CD1dTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 4740US2011044979A1Domain antibody constructDOYLE ANTHONY G·Filed 2010·Application pending·0 cites
- 4837US8932588B2Treatment of cancer involving mutated KRAS or BRAF genesKIENZLE NORBERT A·Filed 2010·Granted Jan 13, 2015·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Anthony G. Doyle files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →